State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 3,331,535 shares of Corvus Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 3,331,535 shares of Corvus Pharmaceuticals common stock (CUSIP 221015100).
  • Percent of class: The reported stake represents 4% of the outstanding class of common stock, according to the filing.
  • Shared voting power: State Street disclosed shared voting power over 3,233,973 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over all 3,331,535 shares, with sole dispositive power of 0.
  • Subsidiaries involved: Five subsidiaries are identified as having acquired the securities, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, each classified as an investment adviser (IA).
  • Event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Signing officer: The statement was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

State Street's Schedule 13G Filing on Corvus Pharmaceuticals Holdings

State Street Corporation, a holding company organized in Massachusetts with its principal office at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing a position in Corvus Pharmaceuticals Inc., a company headquartered at 863 Mitten Road, Suite 102, Burlingame, California, 94010. The filing covers common stock with CUSIP number 221015100, and the triggering event date is listed as September 30, 2026.

According to the filing, State Street's aggregate beneficial ownership stands at 3,331,535 shares, representing 4% of the class. The filing reports no sole voting or sole dispositive power. Shared voting power covers 3,233,973 shares, while shared dispositive power extends to the full 3,331,535 shares. The filing identifies five subsidiaries through which the securities were acquired: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd., each classified as an investment adviser.

The filing was made under the ownership-of-5-percent-or-less provision (Item 5), consistent with the reported 4% stake. State Street certified, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Senior Vice President Alok Maheshwary on November 9, 2026.

What Was Disclosed

State Street Corporation disclosed a 4% beneficial ownership position in Corvus Pharmaceuticals Inc. common stock, totaling 3,331,535 shares, with all dispositive and voting power held on a shared basis through five investment adviser subsidiaries, as of September 30, 2026.